Commonly used oncology drugs decrease antifungal effectiveness against candida and aspergillus species

Arielle Butts, Parker Reitler, Wenbo Ge, Jarrod Fortwendel, Glen Palmer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The incidence of invasive fungal infections has risen significantly in recent decades as medical interventions have become increasingly aggressive. These infections are extremely difficult to treat due to the extremely limited repertoire of systemic antifungals, the development of drug resistance, and the extent to which the patient’s immune function is compromised. Even when the appropriate antifungal therapies are administered in a timely fashion, treatment failure is common, even in the absence of in vitro microbial resistance. In this study, we screened a small collection of FDA-approved oncolytic agents for compounds that impact the efficacy of the two most widely used classes of systemic antifungals against Candida albicans, Candida glabrata, and Aspergillus fumigatus. We have identified several drugs that enhance fungal growth in the presence of azole antifungals and examine the potential that these drugs directly affect fungal fitness, specifically antifungal susceptibility, and may be contributing to clinical treatment failure.

Original languageEnglish (US)
Article numbere00504-18
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Aspergillus
Treatment Failure
Candida
Fungal Drug Resistance
Candida glabrata
Azoles
Aspergillus fumigatus
Candida albicans
Pharmaceutical Preparations
Incidence
Growth
Infection
Therapeutics
In Vitro Techniques
Invasive Fungal Infections

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Commonly used oncology drugs decrease antifungal effectiveness against candida and aspergillus species. / Butts, Arielle; Reitler, Parker; Ge, Wenbo; Fortwendel, Jarrod; Palmer, Glen.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 7, e00504-18, 01.07.2018.

Research output: Contribution to journalArticle

@article{cb8ff305eb724522827bc29f5c1c80b7,
title = "Commonly used oncology drugs decrease antifungal effectiveness against candida and aspergillus species",
abstract = "The incidence of invasive fungal infections has risen significantly in recent decades as medical interventions have become increasingly aggressive. These infections are extremely difficult to treat due to the extremely limited repertoire of systemic antifungals, the development of drug resistance, and the extent to which the patient’s immune function is compromised. Even when the appropriate antifungal therapies are administered in a timely fashion, treatment failure is common, even in the absence of in vitro microbial resistance. In this study, we screened a small collection of FDA-approved oncolytic agents for compounds that impact the efficacy of the two most widely used classes of systemic antifungals against Candida albicans, Candida glabrata, and Aspergillus fumigatus. We have identified several drugs that enhance fungal growth in the presence of azole antifungals and examine the potential that these drugs directly affect fungal fitness, specifically antifungal susceptibility, and may be contributing to clinical treatment failure.",
author = "Arielle Butts and Parker Reitler and Wenbo Ge and Jarrod Fortwendel and Glen Palmer",
year = "2018",
month = "7",
day = "1",
doi = "10.1128/AAC.00504-18",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Commonly used oncology drugs decrease antifungal effectiveness against candida and aspergillus species

AU - Butts, Arielle

AU - Reitler, Parker

AU - Ge, Wenbo

AU - Fortwendel, Jarrod

AU - Palmer, Glen

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The incidence of invasive fungal infections has risen significantly in recent decades as medical interventions have become increasingly aggressive. These infections are extremely difficult to treat due to the extremely limited repertoire of systemic antifungals, the development of drug resistance, and the extent to which the patient’s immune function is compromised. Even when the appropriate antifungal therapies are administered in a timely fashion, treatment failure is common, even in the absence of in vitro microbial resistance. In this study, we screened a small collection of FDA-approved oncolytic agents for compounds that impact the efficacy of the two most widely used classes of systemic antifungals against Candida albicans, Candida glabrata, and Aspergillus fumigatus. We have identified several drugs that enhance fungal growth in the presence of azole antifungals and examine the potential that these drugs directly affect fungal fitness, specifically antifungal susceptibility, and may be contributing to clinical treatment failure.

AB - The incidence of invasive fungal infections has risen significantly in recent decades as medical interventions have become increasingly aggressive. These infections are extremely difficult to treat due to the extremely limited repertoire of systemic antifungals, the development of drug resistance, and the extent to which the patient’s immune function is compromised. Even when the appropriate antifungal therapies are administered in a timely fashion, treatment failure is common, even in the absence of in vitro microbial resistance. In this study, we screened a small collection of FDA-approved oncolytic agents for compounds that impact the efficacy of the two most widely used classes of systemic antifungals against Candida albicans, Candida glabrata, and Aspergillus fumigatus. We have identified several drugs that enhance fungal growth in the presence of azole antifungals and examine the potential that these drugs directly affect fungal fitness, specifically antifungal susceptibility, and may be contributing to clinical treatment failure.

UR - http://www.scopus.com/inward/record.url?scp=85049009896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049009896&partnerID=8YFLogxK

U2 - 10.1128/AAC.00504-18

DO - 10.1128/AAC.00504-18

M3 - Article

C2 - 29712657

AN - SCOPUS:85049009896

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

M1 - e00504-18

ER -